Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,713 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dried Clear all
Completed Not applicable Interventional Results available

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

NCT01521507
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
LipiFlow System, Warm Compress Therapy + Lid Scrub
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fayetteville, Arkansas • Laguna Hills, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

NCT01250171
View directory record Official record
Conditions
Dry Eye
Interventions
Secukinumab 10 mg/kg, Canakinumab 10 mg/kg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease

NCT00567177
View directory record Official record
Conditions
Treatment of Dry Eye Disease
Interventions
Restasis, Refresh Plus
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
6400 Fannin Ste 1800, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2010 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

NCT02281500
View directory record Official record
Conditions
Congenital Afibrinogenemia
Interventions
Human Plasma-Derived Fibrinogen Concentrate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

NCT00814944
View directory record Official record
Conditions
Dry Eye
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

NCT01027013
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Lewiston, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 22, 2026, 10:44 PM EDT
Terminated Phase 1 Interventional

Botox vs. Baclofen for Upper Limb Spasticity

NCT00280280
View directory record Official record
Conditions
Spasticity
Interventions
intramuscular Botox versus oral baclofen
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03302273
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Inflammation, Ocular Surface Disease, Ocular Discomfort, Blepharitis
Interventions
Corneal Epithelial Stem Cell Transplant
Other
Lead sponsor
Sloan W. Rush, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 22, 2026, 10:44 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Implant Stability in Autogenous Mineralized and Demineralized Dentin Grafts

NCT05219305
View directory record Official record
Conditions
Edentulous Alveolar Ridge
Interventions
Dental Implant Placement
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 22, 2026, 10:44 PM EDT
Withdrawn Phase 2 Interventional

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

NCT06473974
View directory record Official record
Conditions
Facial Hyperpigmentation
Interventions
Test cosmetic product
Drug
Lead sponsor
Kayuraeffect, LLP
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 12 Week Study to Evaluate the Efficacy of an Eye Cream

NCT05807620
View directory record Official record
Conditions
Periorbital Hyperpigmentation, Periorbital Edema, Fine Lines, Wrinkle
Interventions
Gentle Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 30
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial tears
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 10:44 PM EDT
Terminated Not applicable Interventional

Dry Needling and Functional Improvement

NCT02838394
View directory record Official record
Conditions
Myofascial Trigger Point Pain, Myofascial Pain Syndrome
Interventions
Dry needling, Sham dry needling
Procedure · Other
Lead sponsor
Brigham Young University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 22, 2026, 10:44 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms

NCT01382810
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Altaire Gel forming solution, Refresh Tears
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Lake Villa, Illinois • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional Results available

Berries, Bugs, and the Blues

NCT05817383
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Freeze-dried Blueberry Powder, Placebo Powder
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 10:44 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Anti-Glaucoma Medications on the Ocular Surface

NCT01315574
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects Grapes on Health Indices

NCT01674231
View directory record Official record
Conditions
Obesity, Inflammation, Cardiovascular Disease, Oxidative Stress
Interventions
Grape in the form of freeze-dried whole grape powder, Grape powder placebo
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

NCT05493111
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional

The Health Effects of a Blueberry Enriched Diet on Obese Children

NCT01809795
View directory record Official record
Conditions
Obesity
Interventions
Blueberry Smoothie, Sham Smoothie
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional

The Home Blood Pressure (BP) Trial

NCT05159999
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Dry weight target adjustment, Anti-hypertensive medications
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 22, 2026, 10:44 PM EDT
Completed Not applicable Interventional

A Mediation Analysis Investigating Dry Needling Treatment Mechanisms in a Chronic Low Back Pain Population

NCT06940492
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP)
Interventions
Dry needling
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 10:44 PM EDT